NEW YORK, NY / ACCESSWIRE / March 20, 2017 / As both Geron and Galena Biopharma show signs of biotech life with their FDA trial advancements, the stocks also have a common problem – how to convince investors that they are a good investment for the long term. Many biotech stock prices flail around and investors do not know which direction they are headed. This is because the sector consists of a variety of companies that are either bought out or whose FDA Phase 3 trials are insufficient for final FDA approval. Today's good news can quickly become tomorrow's reason to sell yesterday. Here are two stocks worth watching for different reasons.
RDI Initiates Coverage:
Geron Corporation https://ub.rdinvesting.com/news/?ticker=GERN
Galena Biopharma Inc. https://ub.rdinvesting.com/news/?ticker=GALE
Geron Corporation closed up 1 cent a share on Friday, to close at $2.10. After hours trading made no change to the $2.13 mid-afternoon high it saw before dropping down. Geron Corporation is a biotechnology company that focuses on the development of pharmaceuticals and has a very small revenue stream it is generating from collaboration and license fees and royalties as of now. The price swings are an indicator of stock price volatility, and potential takeover rumors. The recent rating given to the stock by Zacks Investment Research has given the company a "buy" rating largely based on its estimated future earnings. The company is categorized as a health services company that is developing treatments for cancer treatments using stem cell research. Geron has reported a loss of $0.19 a share for year 2016.
Access RDI's Geron Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=GERN
Galena Biopharma was up 1 cent a share on Friday to close at 63 cents per share. The company's lead candidate drug is GALE-301, a cancer immunotherapy drug intended to be used for the prevention of ovarian cancer recurrence and endometrial cancer in patients. Bijan Nejadnik, M.D., the company's Executive Vice President and Chief Medical Officer said during a Friday presentation of the FDA Phase 1 and 2 results, "This final data from our early stage clinical trial demonstrates that GALE-301 is well tolerated and we were able to obtain statistically significant disease free survival in a small number of patients treated with the optimal dose." The statement came as positive news for investors, but were reminded of at least one pending litigation filed by investors in April of last year. Galena has reported a net loss of $0.49 a share and $2.36 a share for the fourth quarter and full year of 2016 respectively.
Access RDI's Galena Biopharma Research Report at: https://ub.rdinvesting.com/news/?ticker=GALE
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.